• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在注定会发展为前置胎盘的妊娠中,妊娠早期存在异常的微小RNA表达谱。

Abnormal microRNA expression profile at early stages of gestation in pregnancies destined to develop placenta previa.

作者信息

Hromadnikova Ilona, Kotlabova Katerina, Krofta Ladislav

机构信息

Department of Molecular Biology and Cell Pathology, Third Faculty of Medicine, Charles University, Prague, Czechia.

Institute for the Care of the Mother and Child, Third Faculty of Medicine, Charles University, Prague, Czechia.

出版信息

Front Med (Lausanne). 2024 Dec 3;11:1469855. doi: 10.3389/fmed.2024.1469855. eCollection 2024.

DOI:10.3389/fmed.2024.1469855
PMID:39691371
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11650449/
Abstract

BACKGROUND

Placenta previa is the abnormal implantation of the placenta into the lower segment of the uterus, is associated with adverse maternal and fetal outcomes such as placenta accreta spectrum disorders, antepartum and postpartum hemorrhage, fetal growth restriction, prematurity, stillbirth and neonatal death, thrombophlebitis, and septicemia. The aim of the study was to assess retrospectively how the later onset of placenta previa affects the microRNA expression profile in the whole peripheral blood during the first trimester of gestation.

METHODS

Regarding the occurrence of the association between aberrant microRNA expression profiles at early stages of gestation and later onset of various pregnancy-related complications, we selected for the study pregnancies developing placenta previa as the only pregnancy-related disorder. In total, 24 singleton pregnancies diagnosed with placenta previa that underwent first-trimester prenatal screening and delivered on-site within the period November 2012-May 2018 were included in the study. Overall, 80 normal pregnancies that delivered appropriate-for-gestational age newborns after completing 37 weeks of gestation were selected as the control group based on the equality of the length of biological sample storage.

RESULTS

Downregulation of multiple microRNAs (miR-20b-5p, miR-24-3p, miR-26a-5p, miR-92a-3p, miR-103a-3p, miR-130b-3p, miR-133a-3p, miR-145-5p, miR-146a-5p, miR-155-5p, miR-181a-5p, miR-195-5p, miR-210-3p, miR-342-3p, and miR-574-3p) was observed in pregnancies destined to develop placenta previa. The combination of seven microRNAs (miR-130b-3p, miR-145-5p, miR-155-5p, miR-181a-5p, miR-210-3p, miR-342-3p, and miR-574-3p) showed the highest accuracy (AUC 0.937, < 0.001, 100.0% sensitivity, 83.75% specificity) to differentiate, at early stages of gestation, between pregnancies with a normal course of gestation and those with placenta previa diagnosed in the second half of pregnancy. Overall, 75% of pregnancies destined to develop placenta previa were correctly identified at 10.0% FPR.

CONCLUSION

Consecutive large-scale analyses must be performed to verify the reliability of the proposed novel early predictive model for placenta previa occurring as the only pregnancy-related disorder.

摘要

背景

前置胎盘是指胎盘异常植入子宫下段,与诸如胎盘植入谱系疾病、产前和产后出血、胎儿生长受限、早产、死产和新生儿死亡、血栓性静脉炎及败血症等不良母婴结局相关。本研究的目的是回顾性评估妊娠早期发生的前置胎盘如何影响妊娠早期外周血中的微小RNA表达谱。

方法

鉴于妊娠早期异常微小RNA表达谱与各种妊娠相关并发症的后期发生之间存在关联,我们选择仅发生前置胎盘这一妊娠相关疾病的妊娠进行研究。本研究共纳入24例诊断为前置胎盘且在2012年11月至2018年5月期间接受了孕早期产前筛查并在当地分娩的单胎妊娠。总体而言,基于生物样本储存时间相等,选择80例在妊娠37周后分娩出适于胎龄新生儿的正常妊娠作为对照组。

结果

在注定会发生前置胎盘的妊娠中观察到多种微小RNA(miR-20b-5p、miR-24-3p、miR-26a-5p、miR-92a-3p、miR-103a-3p、miR-130b-3p、miR-133a-3p、miR-145-5p、miR-146a-5p、miR-155-5p、miR-181a-5p、miR-195-5p、miR-210-3p、miR-342-3p和miR-574-3p)表达下调。七种微小RNA(miR-130b-3p、miR-145-5p、miR-155-5p、miR-181a-5p、miR-210-3p、miR-342-3p和miR-574-3p)的组合在妊娠早期区分正常妊娠过程的妊娠和妊娠后半期诊断为前置胎盘的妊娠时显示出最高准确性(曲线下面积0.937,P<0.001,敏感性100.0%,特异性83.75%)。总体而言,在10.0%的假阳性率下,75%注定会发生前置胎盘的妊娠被正确识别。

结论

必须进行连续的大规模分析,以验证所提出的作为唯一妊娠相关疾病发生的前置胎盘新型早期预测模型的可靠性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91f0/11650449/2046c6ef1b39/fmed-11-1469855-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91f0/11650449/a534a6b0b837/fmed-11-1469855-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91f0/11650449/2046c6ef1b39/fmed-11-1469855-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91f0/11650449/a534a6b0b837/fmed-11-1469855-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91f0/11650449/2046c6ef1b39/fmed-11-1469855-g002.jpg

相似文献

1
Abnormal microRNA expression profile at early stages of gestation in pregnancies destined to develop placenta previa.在注定会发展为前置胎盘的妊娠中,妊娠早期存在异常的微小RNA表达谱。
Front Med (Lausanne). 2024 Dec 3;11:1469855. doi: 10.3389/fmed.2024.1469855. eCollection 2024.
2
First Trimester Prediction of Preterm Delivery in the Absence of Other Pregnancy-Related Complications Using Cardiovascular-Disease Associated MicroRNA Biomarkers.使用心血管疾病相关微小RNA生物标志物在无其他妊娠相关并发症情况下对早产进行孕早期预测。
Int J Mol Sci. 2022 Apr 1;23(7):3951. doi: 10.3390/ijms23073951.
3
First trimester prediction models for small-for- gestational age and fetal growth restricted fetuses without the presence of preeclampsia.无子痫前期的小于胎龄儿和胎儿生长受限的早孕期预测模型。
Mol Cell Probes. 2023 Dec;72:101941. doi: 10.1016/j.mcp.2023.101941. Epub 2023 Nov 16.
4
First-Trimester Screening for Miscarriage or Stillbirth-Prediction Model Based on MicroRNA Biomarkers.早孕期流产或死胎筛查——基于 microRNA 生物标志物的预测模型。
Int J Mol Sci. 2023 Jun 14;24(12):10137. doi: 10.3390/ijms241210137.
5
First-Trimester Screening for Fetal Growth Restriction and Small-for-Gestational-Age Pregnancies without Preeclampsia Using Cardiovascular Disease-Associated MicroRNA Biomarkers.使用心血管疾病相关的微小RNA生物标志物对无先兆子痫的胎儿生长受限和小于胎龄妊娠进行孕早期筛查。
Biomedicines. 2022 Mar 19;10(3):718. doi: 10.3390/biomedicines10030718.
6
Cardiovascular Disease-Associated MicroRNAs as Novel Biomarkers of First-Trimester Screening for Gestational Diabetes Mellitus in the Absence of Other Pregnancy-Related Complications.心血管疾病相关 microRNAs 作为无其他妊娠相关并发症的妊娠期糖尿病第一孕期筛查的新型生物标志物。
Int J Mol Sci. 2022 Sep 13;23(18):10635. doi: 10.3390/ijms231810635.
7
Cardiovascular Disease-Associated MicroRNA Dysregulation during the First Trimester of Gestation in Women with Chronic Hypertension and Normotensive Women Subsequently Developing Gestational Hypertension or Preeclampsia with or without Fetal Growth Restriction.患有慢性高血压的女性以及随后发生妊娠期高血压或子痫前期(伴或不伴有胎儿生长受限)的血压正常女性在妊娠早期与心血管疾病相关的微小RNA失调。
Biomedicines. 2022 Jan 25;10(2):256. doi: 10.3390/biomedicines10020256.
8
Cardiovascular and Cerebrovascular Disease Associated microRNAs Are Dysregulated in Placental Tissues Affected with Gestational Hypertension, Preeclampsia and Intrauterine Growth Restriction.与心血管和脑血管疾病相关的微小RNA在患有妊娠期高血压、先兆子痫和胎儿生长受限的胎盘组织中表达失调。
PLoS One. 2015 Sep 22;10(9):e0138383. doi: 10.1371/journal.pone.0138383. eCollection 2015.
9
Diabetes Mellitus and Cardiovascular Risk Assessment in Mothers with a History of Gestational Diabetes Mellitus Based on Postpartal Expression Profile of MicroRNAs Associated with Diabetes Mellitus and Cardiovascular and Cerebrovascular Diseases.基于与糖尿病、心血管和脑血管疾病相关的 microRNAs 在产后表达谱的妊娠期糖尿病母亲的糖尿病和心血管风险评估。
Int J Mol Sci. 2020 Mar 31;21(7):2437. doi: 10.3390/ijms21072437.
10
Gestational hypertension, preeclampsia and intrauterine growth restriction induce dysregulation of cardiovascular and cerebrovascular disease associated microRNAs in maternal whole peripheral blood.妊娠期高血压、子痫前期和胎儿生长受限会导致孕妇外周血中与心血管和脑血管疾病相关的微小RNA失调。
Thromb Res. 2016 Jan;137:126-140. doi: 10.1016/j.thromres.2015.11.032. Epub 2015 Nov 22.

引用本文的文献

1
Maternal plasma microRNA profiles in twin-twin transfusion syndrome and normal monochorionic twin pregnancies.双胎输血综合征及正常单绒毛膜双胎妊娠中的母血微小RNA谱
Front Mol Biosci. 2025 Jul 23;12:1597215. doi: 10.3389/fmolb.2025.1597215. eCollection 2025.

本文引用的文献

1
Risk factors of severe postpartum hemorrhage in pregnant women with placenta previa or low-lying placenta: a retrospective cohort study.前置胎盘或低置胎盘孕妇产后出血严重的危险因素:一项回顾性队列研究。
BMC Pregnancy Childbirth. 2024 Oct 15;24(1):674. doi: 10.1186/s12884-024-06876-3.
2
First-trimester predictive models for adverse pregnancy outcomes-a base for implementation of strategies to prevent cardiovascular disease development.孕早期不良妊娠结局预测模型——预防心血管疾病发展策略实施的基础
Front Cell Dev Biol. 2024 Sep 4;12:1461547. doi: 10.3389/fcell.2024.1461547. eCollection 2024.
3
Maternal and Perinatal Outcomes in Placenta Previa: A Comprehensive Review of Evidence.
前置胎盘的母儿结局:证据的全面综述
Cureus. 2024 May 6;16(5):e59737. doi: 10.7759/cureus.59737. eCollection 2024 May.
4
First-trimester screening for placenta accreta spectrum.早孕期胎盘植入谱系疾病筛查。
Am J Obstet Gynecol MFM. 2024 May;6(5):101329. doi: 10.1016/j.ajogmf.2024.101329. Epub 2024 Mar 5.
5
Serum exosomal microRNA pathway activation in placenta accreta spectrum: pathophysiology and detection.胎盘植入谱系中血清外泌体微小RNA通路激活:病理生理学与检测
AJOG Glob Rep. 2024 Feb 10;4(1):100319. doi: 10.1016/j.xagr.2024.100319. eCollection 2024 Feb.
6
Ultrasonographic cervical length assessment in pregnancies with placenta previa and risk of perinatal adverse outcomes: a systematic review and meta-analysis.前置胎盘妊娠的超声宫颈长度评估与围产期不良结局风险:一项系统评价和荟萃分析
Am J Obstet Gynecol MFM. 2024 May;6(5S):101172. doi: 10.1016/j.ajogmf.2023.101172. Epub 2023 Sep 30.
7
Risk factors and perinatal outcomes for persistent placenta previa in nulliparas.初产妇前置胎盘持续存在的危险因素及围产期结局
Am J Obstet Gynecol MFM. 2023 Oct;5(10):101136. doi: 10.1016/j.ajogmf.2023.101136. Epub 2023 Aug 18.
8
Routine screening for placenta accreta spectrum.胎盘植入谱系疾病的常规筛查
Best Pract Res Clin Obstet Gynaecol. 2023 Aug;90:102392. doi: 10.1016/j.bpobgyn.2023.102392. Epub 2023 Jul 22.
9
First-Trimester Screening for Miscarriage or Stillbirth-Prediction Model Based on MicroRNA Biomarkers.早孕期流产或死胎筛查——基于 microRNA 生物标志物的预测模型。
Int J Mol Sci. 2023 Jun 14;24(12):10137. doi: 10.3390/ijms241210137.
10
First-Trimester Screening for HELLP Syndrome-Prediction Model Based on MicroRNA Biomarkers and Maternal Clinical Characteristics.早孕期 HELLP 综合征筛查——基于 microRNA 生物标志物和母体临床特征的预测模型。
Int J Mol Sci. 2023 Mar 8;24(6):5177. doi: 10.3390/ijms24065177.